<VariationArchive VariationID="1459539" VariationName="NC_000017.10:g.(?_17116310)_(17117959_?)del" VariationType="Deletion" Accession="VCV001459539" Version="9" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1484729" VariationID="1459539">
      <GeneList>
        <Gene Symbol="FLCN" FullName="folliculin" GeneID="201163" HGNC_ID="HGNC:27310" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17p11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="17212212" stop="17237330" display_start="17212212" display_stop="17237330" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="17115525" stop="17140501" display_start="17115525" display_stop="17140501" Strand="-" />
          </Location>
          <OMIM>607273</OMIM>
          <Haploinsufficiency last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000017.10:g.(?_17116310)_(17117959_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="17116310" innerStop="17117959" display_start="17116310" display_stop="17117959" variantLength="1650" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_17116310)_(17117959_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_17116310)_(17117959_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000017.10:g.(?_17116310)_(17117959_?)del AND Birt-Hogg-Dube syndrome" Accession="RCV001975247" Version="8">
        <ClassifiedConditionList TraitSetID="860">
          <ClassifiedCondition DB="MedGen" ID="C0346010">Birt-Hogg-Dube syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-03-19" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-03-19" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15852235</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17028174</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18403135</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18663353</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19802896</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20413710</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22977732</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24393238</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27229674</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="860" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1028" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Birt-Hogg-Dube syndrome</ElementValue>
                <XRef ID="MONDO:0800444" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">BHD syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Birt Hogg Dubé syndrome</ElementValue>
                <XRef ID="1263460007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BHD</ElementValue>
                <XRef Type="MIM" ID="135150" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">The clinical characteristics of Birt-Hogg-Dubé syndrome (BHDS) include cutaneous manifestations (fibrofolliculomas, acrochordons, angiofibromas, oral papules, cutaneous collagenomas, and epidermal cysts), pulmonary cysts/history of pneumothorax, and various types of renal tumors. Disease severity can vary significantly even within the same family. Skin lesions typically appear between the second and fourth decades of life and typically increase in size and number with age. Lung cysts are often bilateral and multifocal; most individuals are asymptomatic but at high risk for spontaneous pneumothorax. Individuals with BHDS are at a sevenfold increased risk for renal tumors that can be bilateral and multifocal; median age of renal tumor diagnosis is 48 years. The most common renal tumors are a hybrid of oncocytoma and chromophobe histologic cell types (oncocytic hybrid tumor) and chromophobe histologic cell types. Some families have renal tumor(s) and/or spontaneous pneumothorax without cutaneous manifestations.</Attribute>
                <XRef ID="NBK1522" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2322" />
                <XRef ID="2322" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301695</ID>
                <ID Source="BookShelf">NBK1522</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Birt-Hogg-Dubé syndrome">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/bhd-syndrome</URL>
                <CitationText>PDQ® Cancer Genetics Editorial Board. PDQ Birt-Hogg-Dubé Syndrome. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="122" DB="Orphanet" />
              <XRef ID="C0346010" DB="MedGen" />
              <XRef ID="MONDO:0800444" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS135150" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4264003" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_144997.5_17_Deletion (exon 14)_17116309_17117959|MedGen:C0346010" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002246564" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17028174</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18403135</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17028174</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18403135</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18663353</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22977732</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15852235</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19802896</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20413710</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24393238</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27229674</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant is expected to disrupt the C-terminus of the FLCN protein, which contains the minimal binding domain for interaction with FNIP1/2 proteins (residues 517-579) (PMID: 17028174, 18403135). This domain has been shown to be important for AMPK-mediated mTOR signaling pathways (PMID: 17028174, 18403135, 18663353, 22977732). While functional studies have not been performed to directly test the effect of this variant on FLCN protein function, this suggests that disruption of this region of the protein may be causative of disease. Other variant(s) that disrupt this region (p.Arg527*, p.Gln533*) have been determined to be pathogenic (PMID: 15852235, 19802896, Invitae). A similar complex rearrangement has not been reported. However, deletion of exon 14 has been observed in individuals with clinical features of Birt-Hogg-Dub√© syndrome (PMID: 20413710, 24393238, 27229674). This variant is a complex rearrangement that results in the deletion of exon 14. Although the exact nature of the event is unclear, it also appears to involve a copy number gain of exon 11, which has been inverted and inserted in place of exon 14. The rearrangement is expected to create a truncated protein product or disrupt mRNA translation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FLCN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_17116310)_(17117959_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0346010" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4264003" TraitType="Disease" MappingType="XRef" MappingValue="C0346010" MappingRef="MedGen">
        <MedGen CUI="C0346010" Name="Birt-Hogg-Dube syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

